These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

601 related items for PubMed ID: 15870721

  • 21. Improved quality of life after long-term treatment with the bisphosphonate ibandronate in patients with metastatic bone disease due to breast cancer.
    Diel IJ, Body JJ, Lichinitser MR, Kreuser ED, Dornoff W, Gorbunova VA, Budde M, Bergström B, MF 4265 Study Group.
    Eur J Cancer; 2004 Jul; 40(11):1704-12. PubMed ID: 15251160
    [Abstract] [Full Text] [Related]

  • 22. Zoledronic acid in the treatment of metastatic breast cancer.
    Lluch A, Cueva J, Ruiz-Borrego M, Ponce J, Pérez-Fidalgo JA.
    Anticancer Drugs; 2014 Jan; 25(1):1-7. PubMed ID: 24100278
    [Abstract] [Full Text] [Related]

  • 23. Bisphosphonates and metastatic breast carcinoma.
    Lipton A.
    Cancer; 2003 Feb 01; 97(3 Suppl):848-53. PubMed ID: 12548585
    [Abstract] [Full Text] [Related]

  • 24. Retrospective database analysis of the effect of zoledronic acid on skeletal-related events and mortality in women with breast cancer and bone metastasis in a managed care plan.
    Henk HJ, Kaura S.
    J Med Econ; 2012 Feb 01; 15(1):175-84. PubMed ID: 22017235
    [Abstract] [Full Text] [Related]

  • 25. Percutaneous vertebroplasty combined with zoledronic acid for the treatment of painful osteolytic spinal metastases in patients with breast cancer.
    Zhang J, Wang Y, Han K, Tang L, Hu H, Wu C, Shen Z, Sun Y, Yao Y.
    J Vasc Interv Radiol; 2013 Dec 01; 24(12):1861-7. PubMed ID: 24144536
    [Abstract] [Full Text] [Related]

  • 26. Pain outcomes in patients with advanced breast cancer and bone metastases: results from a randomized, double-blind study of denosumab and zoledronic acid.
    Cleeland CS, Body JJ, Stopeck A, von Moos R, Fallowfield L, Mathias SD, Patrick DL, Clemons M, Tonkin K, Masuda N, Lipton A, de Boer R, Salvagni S, Oliveira CT, Qian Y, Jiang Q, Dansey R, Braun A, Chung K.
    Cancer; 2013 Feb 15; 119(4):832-8. PubMed ID: 22951813
    [Abstract] [Full Text] [Related]

  • 27. Denosumab and bone metastases. No better than a bisphosphonate.
    Prescrire Int; 2012 Sep 15; 21(130):204-6. PubMed ID: 23016249
    [Abstract] [Full Text] [Related]

  • 28. Safety and efficacy of zoledronic acid rapid infusion in lung cancer patients with bone metastases: a single institution experience.
    Kotteas E, Alamara C, Kiagia M, Pantazopoulos K, Boufas A, Provata A, Charpidou A, Syrigos KN.
    Anticancer Res; 2008 Sep 15; 28(1B):529-33. PubMed ID: 18383897
    [Abstract] [Full Text] [Related]

  • 29. A prospective, multicenter, open-label trial of zoledronic acid in patients with hormone refractory prostate cancer.
    Hong SJ, Cho KS, Cho HY, Ahn H, Kim CS, Chung BH.
    Yonsei Med J; 2007 Dec 31; 48(6):1001-8. PubMed ID: 18159593
    [Abstract] [Full Text] [Related]

  • 30. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma.
    Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L, Chin JL, Vinholes JJ, Goas JA, Chen B, Zoledronic Acid Prostate Cancer Study Group.
    J Natl Cancer Inst; 2002 Oct 02; 94(19):1458-68. PubMed ID: 12359855
    [Abstract] [Full Text] [Related]

  • 31. Zoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: a report from the Austrian Breast and Colorectal Cancer Study Group.
    Gnant MF, Mlineritsch B, Luschin-Ebengreuth G, Grampp S, Kaessmann H, Schmid M, Menzel C, Piswanger-Soelkner JC, Galid A, Mittlboeck M, Hausmaninger H, Jakesz R, Austrian Breast and Colorectal Cancer Study Group.
    J Clin Oncol; 2007 Mar 01; 25(7):820-8. PubMed ID: 17159195
    [Abstract] [Full Text] [Related]

  • 32. Optimal management of metastatic bone disease.
    Major P.
    Eur J Oncol Nurs; 2007 Mar 01; 11 Suppl 2():S32-7. PubMed ID: 17804294
    [Abstract] [Full Text] [Related]

  • 33. Comparative evaluation of safety and efficacy of pamidronate and zoledronic acid in multiple myeloma patients (single center experience).
    Kraj M, Pogłód R, Maj S, Pawlikowski J, Sokołowska U, Szczepanik J.
    Acta Pol Pharm; 2002 Mar 01; 59(6):478-82. PubMed ID: 12669777
    [Abstract] [Full Text] [Related]

  • 34. Clinical efficacy and safety of zoledronic acid in prostate and breast cancer.
    Doggrell SA.
    Expert Rev Anticancer Ther; 2009 Sep 01; 9(9):1211-8. PubMed ID: 19761424
    [Abstract] [Full Text] [Related]

  • 35. Biomarker alterations with metronomic use of low-dose zoledronic acid for breast cancer patients with bone metastases and potential clinical significance.
    Zhao X, Xu X, Guo L, Ragaz J, Guo H, Wu J, Shao Z, Zhu J, Guo X, Chen J, Zhu B, Wang Z, Hu X.
    Breast Cancer Res Treat; 2010 Dec 01; 124(3):733-43. PubMed ID: 20882405
    [Abstract] [Full Text] [Related]

  • 36. Skeletal complications in patients with bone metastases from renal cell carcinoma and therapeutic benefits of zoledronic acid.
    Lipton A, Colombo-Berra A, Bukowski RM, Rosen L, Zheng M, Urbanowitz G.
    Clin Cancer Res; 2004 Sep 15; 10(18 Pt 2):6397S-403S. PubMed ID: 15448038
    [Abstract] [Full Text] [Related]

  • 37. An audit to determine the time taken to administer intravenous bisphosphonate infusions in patients diagnosed with metastatic breast cancer to bone in a hospital setting.
    Barrett-Lee P, Bloomfield D, Dougherty L, Harries M, Laing R, Patel H, Walker M.
    Curr Med Res Opin; 2007 Jul 15; 23(7):1575-82. PubMed ID: 17559749
    [Abstract] [Full Text] [Related]

  • 38. Cost-effectiveness of denosumab versus zoledronic acid in the management of skeletal metastases secondary to breast cancer.
    Snedecor SJ, Carter JA, Kaura S, Botteman MF.
    Clin Ther; 2012 Jun 15; 34(6):1334-49. PubMed ID: 22578308
    [Abstract] [Full Text] [Related]

  • 39. Combined therapy of Sr-89 and zoledronic acid in patients with painful bone metastases.
    Storto G, Klain M, Paone G, Liuzzi R, Molino L, Marinelli A, Soricelli A, Pace L, Salvatore M.
    Bone; 2006 Jul 15; 39(1):35-41. PubMed ID: 16434248
    [Abstract] [Full Text] [Related]

  • 40. Everolimus and zoledronic acid in patients with renal cell carcinoma with bone metastases: a randomized first-line phase II trial.
    Broom RJ, Hinder V, Sharples K, Proctor J, Duffey S, Pollard S, Fong PC, Forgeson G, Harris DL, Jameson MB, O'Donnell A, North RT, Deva S, Hanning FJ, Grey A, Findlay MP.
    Clin Genitourin Cancer; 2015 Feb 15; 13(1):50-8. PubMed ID: 25163397
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 31.